This year's LaskerDeBakey Clinical Research Award goes to James Allison for discovering that antibody blockade of the T cell molecule CTLA-4 unleashes the body's immune response against malignant tumors. This has led to development of multiple ''immune checkpoint therapies'' that are prolonging and saving the lives of thousands of cancer patients.
Most advances in cancer therapy have come incrementally and have often been limited to individual types of malignancies. Early approaches that focused on surgical intervention were then supplemented or replaced by radiation therapy and, subsequently, chemotherapy during the last century. With the elucidation of signaling pathways that are dysregulated in cancers, ''targeted therapies,'' most notably protein kinase inhibitors, were successfully adopted during the past two decades. However, despite these advances, durable responses to therapy for most metastatic or inoperable malignancies remain rare.
For this reason, it has long been the dream of physicians to be able to harness the body's own immune defenses to eliminate neoplastic cells, much as they eliminate invading pathogens. Even before the components making up the immune system were known, physicians noted patients whose solid tumors regressed and even disappeared after they suffered skin infections such as erysipelas, typically caused by Streptococci. In famous experiments in the late 19 th century, William Coley injected bacterial extracts into multiple patients suffering from bone or soft tissue sarcomas and over several decades reported responses or complete remissions in a substantial fraction of them. Unfortunately, Coley never conducted controlled trials, and those who succeeded him were unable to garner the needed support to continue testing the ''Coley toxins,'' particularly with the enthusiasm for radiotherapy and chemotherapy at that time.
Only a few immunologists continued to work on cancer therapies after the mid-1950's. Even so, there were some notable successes, such as the antitumor response elicited by local injection of the BCG mycobacterium in bladder cancers and the sporadic successes of IL-2 therapy in melanoma and renal cancer patients. With the spectacular advances in our understanding of T cell immunity and antigen presentation over the past 30 years came the possibility that tumor vaccines could be engineered to elicit protective or therapeutic responses. Yet widespread skepticism remained within the oncology and immunology communities as to whether the body's immune responses could be mobilized to selectively kill tumor cells. Only a few brave souls dared to enter the field of tumor immunology, particularly during a period when most advances in immunology were being made at the level of molecular and cell mechanisms.
It is fair to say that the attitude of physicians and scientists alike toward cancer immunotherapy has changed dramatically during the past 5 years. The stunning successes in treating cancers with anti-CTLA-4 and anti-PD1 ''immune checkpoint therapies'' have spawned newfound optimism that targeting of additional immune pathways and optimization of drug regimens will be effective in numerous cancers and in larger proportions of patients. It is rare that such a sea change can be traced to any one individual, but the advent of checkpoint therapy would have been highly unlikely without the efforts of James Allison, the recipient of this year's LaskerDeBakey Clinical Research Award.
Allison's critical insight built upon the recent elucidation of how T lymphocytes become activated and target cells for killing. He recognized that a recently discovered cell surface receptor called CTLA-4, which turns on after T cell activation to help shut off the response and prevent excessive inflammation, could be targeted therapeutically to potentiate the cytolytic activity of tumor-infiltrating T cells. His studies confirmed that tumortargeting T cells are not uncommon but are often disabled in tumors and hence need to be mobilized to become effective fighters against cancerous tissues.
Allison performed the seminal experiments showing that CTLA-4 blockade unleashes the body's immune response against multiple poorly immunogenic tumors and then embarked on a relentless campaign to find clinical partners who would translate the therapeutic approach to cancer patients. He had to overcome the profound skepticism among physicians that had developed over many decades, and it is a testament to his single-minded zeal that we are celebrating the dawn of a new age in cancer therapies. While this prize has been awarded for a discovery that has resulted in immense clinical benefit, it is based on work deeply rooted in basic science research, much by Allison himself, and is a showcase for the indispensability of animal research in advancing human health. Many individuals have contributed to our understanding of how T cells are activated, but Jim Allison saw the potential of targeting CTLA-4 to treat cancer, helped forge the needed collaboration with an industry partner, and advocated passionately and ultimately successfully for translation to patients. The clinical studies themselves required courage on the part of companies and clinical oncologists, who ventured into uncharted territory by developing new criteria to evaluate responses to the therapy.
Laying the Groundwork
The discovery of CTLA-4 as a therapeutic target in cancer hinged on earlier work that identified T cell surface molecules and their cognate ligands that cooperate with the antigen receptor signaling machinery. The discovery of the T cell antigen receptor (TCR) in the early 1980's, an endeavor to which Allison contributed by identifying a clonally restricted heterodimer in a T cell lymphoma, launched efforts toward understanding how antigen recognition results in T cell activation. It was soon discovered that antibody stimulation of the TCR or its associated signaling machinery, the CD3 complex, was sufficient to activate immortalized cell lines in which much of the early biochemical work on signal transduction was carried out. However, proliferation of primary T cells required a second signal distinct from that transmitted through TCR/CD3. In their influential ''two-signal hypothesis'' in 1970, Bretcher and Cohn had postulated that activation of antibody production by B lymphocytes requires signaling through both the membranebound antigen receptor and an accessory receptor and that cells receiving the antigenic signal alone would be rendered un-responsive or tolerant.
Ron Schwartz and his colleagues found that such a mechanism indeed operates in T lymphocyte activation. Pulsing antigen-presenting cells (APCs) with peptide antigen resulted in IL-2 production and proliferation of T cells bearing receptors specific for that peptide bound to major histocompatibility complex (MHC) molecules. By contrast, exposing antigenspecific T cells to MHC/antigen in lipid bilayers or in chemically fixed APCs induced T cell paralysis, such that they failed to proliferate upon subsequent exposure to unfixed cells (Jenkins and Schwartz, 1987) . This phenomenon, known as anergy, could be overcome if non-antigen-pulsed APCs, even of mismatched MHC, were included in addition to the chemically modified APCs. These experiments were the first to provide convincing evidence that full T cell activation requires engagement of both TCR and a second non-antigen-specific ''costimulatory'' pathway, activated by a ligand on a heterologous cell. These results attracted considerable attention, as they validated the ''two-signal'' hypothesis and also suggested a mechanism for tolerance to self-antigen when recognized by T cells in the absence of co-stimulation.
The Schwartz studies sparked concerted efforts to identify the co-stimulatory molecule. These culminated in studies by Marc Jenkins using human cells (Jenkins et al., 1991) and by Allison using mouse models (Harding et al., 1992) , reporting that an immunoglobulin superfamily member, CD28, had the properties that would be expected of the co-stimulatory molecule. Specifically, crosslinked monoclonal antibodies against CD28 rescued IL-2 production and T cell proliferation when antigen was presented on fixed APCs, whereas monovalent antibodies (Fab) against CD28 rendered the T cells anergic after antigen presentation by unfixed APCs. Shortly thereafter, B7-1 (CD80) and B7-2 (CD86) were discovered to be CD28 ligands expressed by APCs; blocking antibodies against B7-1 inhibited T cell stimulation by antigen-pulsed APCs (Figure 1) . Together, these results presented a pleasing explanation for co-stimulation. However, this was not the end of the story.
CTLA-4 Puts the Brakes on the T Cell Response
During the 1980's, new technologies for gene cloning, including subtractive hybridization and gene transfer, enabled identification of the genes encoding the TCR subunits and multiple other lymphocyte surface glycoproteins. Among these was CTLA-4, cloned by Pierre Golstein from a subtractive cDNA library produced from a CD8 lineage T cell clone. CTLA-4 is an immunoglobulin superfamily member whose locus is closely linked to that of CD28 and whose protein sequence bears substantial homology to CD28, particularly in its extracellular domain. Whereas CD28 is expressed constitutively at the surface of T cells, CTLA-4 expression and translocation to the cell surface are induced only after activation of T cells.
These findings set in motion a number of efforts to manipulate CTLA-4 and thereby regulate T cell function. Peter Linsley, Jeffrey Ledbetter, and colleagues at Bristol-Myers Squibb (BMS) generated a CTLA-4-Ig fusion protein and showed that it bound to both B7-1 and B7-2 with substantially greater affinity than CD28 and was able to block T cell responses to allogeneic cells. Jeff Bluestone's group additionally showed that CTLA-4-Ig was effective when administered to mice, blocking allograft rejection, and he subsequently championed its utility for autoimmune disease therapy. These and other studies led BMS to develop CTLA-4-Ig as Orencia, which is used clinically to treat rheumatoid arthritis.
CTLA-4 was initially proposed to serve as a co-stimulatory molecule, much like CD28, since an anti-CTLA-4 antibody further enhanced the anti-CD28-mediated proliferative effect. However, Bluestone and colleagues, followed soon thereafter by Allison, found that, unlike anti-CD28 Fabs, anti-CTLA-4 monovalent Fab fragments actually enhanced T cell responses to allogeneic cells, while optimal crosslinking with full-length anti-CTLA-4 antibodies inhibited responses to anti-CD3/CD28. Both groups concluded that CTLA-4 expressed in activated T cells interacts with B7 ligands to compete for CD28 binding and also transduces a negative signal that inhibits IL-2 production and T cell proliferation, thus preventing over-activation of the immune system (Krummel and Allison, 1995; Walunas et al., 1994) (Figure 1 ). This conclusion was reinforced by the dramatic phenotype of Ctla4 knockout mice. Unlike CD28-deficient mice, which have relatively subtle defects in their peripheral T cells, CTLA-4-deficient mice developed lethal lymphoproliferation within their first weeks of life, confirming that CTLA-4 has a key role in restraining T cell immune responses.
Targeting CTLA-4 in Cancer
Immunologists have long tried to develop therapeutic vaccines to target tumorspecific antigens, but this endeavor has been largely unsuccessful; even in mouse models, most tumors elicit only weak and ineffective immune responses. Although tumor antigens can be presented to T cells by dendritic cells with co-stimulatory capacity (a phenomenon known as cross-priming), this process is inefficient and may even be thwarted by pre-emptive induction of anergy when infiltrating cytotoxic T cells interact with tumor cells directly and receive only the TCR signal (Figure 1) . The discovery of the CD28-B7 co-stimulation axis raised the prospect that providing co-stimulatory capacity to tumors, which typically lack expression of B7-1 and B7-2, would enhance their immunogenicity and make them more susceptible to immune attack. Indeed, experiments by Lindsey and Allison showed that transfection of multiple types of tumor cells with B7-1 resulted in CD8 T cell-mediated elimination of the tumors after their implantation in mice. Remarkably, exposure of animals to B7-expressing tumors protected them from challenge with the same tumor lacking the co-stimulatory ligand. Enhanced co-stimulation could thus augment durable specific anti-tumor T cell responses.
These results, coupled with the new insights into the role of CTLA-4 as an inhibitory molecule, led Allison to hypothesize that blocking CTLA-4's interaction with B7-1 or B7-2 might release the ''brake'' on the CD8 T cell response, resulting in tumor killing. Consistent with this hypothesis, a pivotal paper by Leach, Krummel, and Allison, published in 1996, showed that anti-CTLA-4 administration resulted in dramatic reduction in the growth of some implanted tumors, even when these antibodies were administered after the tumors had expanded to a substantial size (Leach et al., 1996) . Moreover, anti-CTLA-4-induced rejection of the tumor resulted in immunological memory, leading to long-lived immunity to secondary tumor challenge.
The precise mechanism by which anti-CTLA-4 antibody enhances killing of tumor cells and elicits a durable cytotoxic T cell response is not yet fully defined (Figure 1) . Although the antibody interferes with the ''braking'' function of CTLA-4 in cytotoxic T cells, there is evidence that it also depletes intratumoral regulatory T cells, thus releasing inhibition of tumor-killing CD8 + T cells (Selby et al., 2013 Korman soon moved to Medarex, and he and Lonberg set to work developing fully human antibodies specific for human CTLA-4. One of these antibodies, MDX-010, was chosen for further development and was shown to be effective in macaques, potentiating antibody responses to immunogens and displaying no apparent autoimmune manifestations in that species (Keler et al., 2003) . In 2000, Medarex began phase 1 studies with Allison and clinical investigators at the University of California, San Francisco, evaluating patients with hormone-refractory prostate cancer and metastatic melanoma. Two out of 17 melanoma patients exhibited durable responses, and the therapy was well tolerated, which encouraged further studies at the National Cancer Institute, led by Steven Rosenberg, administering MDX-010 (later named Ipilimumab) to advanced melanoma patients, who also received a melanoma antigen vaccine. Immune cells infiltrated the tumors, and cancer regression was observed in 10%-20% of patients in small cohorts. However, there were severe inflammatory manifestations, including colitis, hepatitis, and hypophysitis, which required steroid therapy.
In 2004, Medarex initiated a collaboration with BMS to expand anti-CTLA-4 clinical trials, but the early optimism for the promise of the therapy was mixed with fear that the FDA would stop the trials due to the adverse side effects and its unclear efficacy. At that time, the response of solid tumors to any therapy was based on criteria developed during the era of chemotherapy, which focused on reduction in tumor size within a limited period of time post-administration. Accordingly, increases in tumor size or the appearance of new lesions during initial trials of anti-CTLA-4 were interpreted to indicate progressive disease and treatment failure. Nevertheless, some astute clinicians noted that many patients classified as having progressive disease went on to have favorable long-term outcomes. During 2004 and 2005 , clinical workshops were convened to discuss how to classify treatment failures versus efficacy in patients receiving immune therapy. One of the conclusions of these discussions was that ''responses to immune therapies may occur after conventional progressive disease'' (Hoos et al., 2007) . The Medarex/BMS clinical team and their academic collaborators, led by Jedd Wolchok, Axel Hoos, Steven O'Day, and Stephen Hodi, published an influential paper in which WHO criteria for assessment of clinical efficacy were reconfigured as immune-related response criteria (irRC) (Wolchok et al., 2009) . By that time, however, Pfizer, which had also initiated an anti-CTLA-4 clinical program with their antibody, Tremelimumab, had already dropped out after perceived failure of a phase 3 trial. To their credit, the Medarex-BMS team persevered in the face of this challenge, particularly after the FDA refused to approve Ipilimumab following a dose-ranging trial that had questionable efficacy and after BMS acquired Medarex in 2009.
The turning point came with a phase 3 trial comparing Ipilimumab to a melanoma peptide vaccine in metastatic melanoma patients who had the HLA A0201 allele (Hodi et al., 2010) . Key to the success of the study was the decision to evaluate overall survival rather than response rate, and in the large study, Ipilimumab monotherapy resulted in more than 20% long-term survival. Significantly, among those who survived 24 months, there were very few relapses (Hodi et al., 2010) , and we now know based on 10 years of follow-up data that about 20% of metastatic melanoma patients are cured with this single agent-a remarkable outcome considering that almost all of those patients would have died with conventional therapy within 1-2 years. The success of this trial led the FDA to finally approve Ipilimumab for the treatment of metastatic melanoma in 2011.
Targeting of PD-1 and PD-L1
At around the time when Ipilimumab was being considered for FDA approval, renewed excitement about immune checkpoint therapy came from clinical studies targeting a second immune inhibitory molecule, PD-1. PD-1 was discovered by Tasuku Honjo in 1992 in a screen for genes expressed during programmed cell death of a T cell hybridoma (Ishida et al., 1992) . PD-1 disruption in mice resulted in inflammatory disease, including a lupus-like syndrome and cardiomyopathy. Although PD-1 is expressed more widely than CTLA-4, its major activity is thought to be in T cells, where it is upregulated during immune responses and transmits inhibitory signals upon interaction with its ligands, PD-L1 and PD-L2. Unlike CTLA-4, which functions mainly during primary immune responses, PD-1 signaling results in ''exhaustion'' of activated T cells, an anergic-like state that is thought to be due to a shift in the utilization of metabolic substrates (Pauken and Wherry, 2015) . Antibody blockade of PD-1 was shown to enhance anti-tumor and anti-viral responses in animal models, suggesting that this could be another immune checkpoint target for cancer.
The Medarex scientists began a program to develop anti-human PD-1 antibodies in the early 2000's (Wang et al., 2014) . This program followed closely on the heels of CTLA-4, and early clinical trials showed promising results in metastatic melanoma, non-small-cell lung cancer (NSCLC), and renal cell carcinoma, with much milder adverse effects than CTLA-4 blockade (Topalian et al., 2012) . Schering Plough also acquired an anti-PD1 antibody developed by Organon, and this was introduced into the clinic as Pembrolizumab, after the company was acquired by Merck, and was approved by the FDA for treating advanced melanoma in 2014. The BMS drug, Nivolumab, was approved very shortly thereafter.
Future Prospects for Immune Checkpoint Therapy
Even though the initial CTLA-4 data were eventually accepted by immunologists and medical oncologists, this acceptance was grudging, because melanoma was thought to be an ''immunologically responsive'' tumor; indeed, melanomas occasionally regress by themselves. The finding that anti-PD-1 had activity against NSCLC was a dramatic refutation of this notion and sparked the enthusiasm seen today for immune therapy. During the past 2-3 years, outcomes of clinical trials with Ipilimumab and the PD-1 or PD-L1 inhibitors, alone or in combination, have dominated the news coming out of clinical oncology meetings. Combination therapy blocking both checkpoint pathways has been particularly effective, with response rates in advanced melanoma of over 80%.
The biopharmaceutical industry has embraced immunotherapy with unbridled enthusiasm, and acquisitions and licensing deals for new approaches are in the news almost every week. New checkpoint targets, including negative regulators of both adaptive and innate immune cells, are being actively investigated, as are combination therapies with cytokines, co-stimulatory molecules, antigen vaccines, and small-molecule modulators of signaling pathways and enzymes. The control of many cancers will likely require combining immune therapies with targeted therapies, conventional chemotherapy, and radiation therapy to maximize efficacy and limit toxicity.
There are obviously many questions that remain to be answered, including why only certain tumors are effectively targeted by immune checkpoint therapy and why some patients but not others respond to the therapy. Answers to these and other questions will require sequencing of tumor genomes to elucidate the role of mutations and neo-antigens, combined with sophisticated monitoring of the immune cells and the microenvironments within different types of tumors.
James Allison appreciated early on the importance of immune monitoring in patients receiving immune checkpoint therapy. Indeed, in order to be closer to the patients, their invaluable tumor-derived biological specimens, and the clinicians providing treatment, he moved his laboratory from the University of California at Berkeley to the Memorial Sloan Kettering Cancer Center in 2004 and, subsequently, to the MD Anderson Cancer Center. This year's well-deserved Lasker Prize recognizes the impact of Allison's vision on the many thousands of cancer patients already benefitting from the clinical development of immune checkpoint inhibitors. The change in attitude of clinical oncologists and immunologists toward the place of immune modulation in combatting cancer guarantees that there will be many exciting advances in immune-based therapies in the years ahead.
